(DRTS) Alpha Tau Medical Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DRTS) Alpha Tau Medical Ltd. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Alpha Tau Medical Ltd. BCG Matrix helps you see how the company’s products or business units fit into the classic Stars, Cash Cows, Question Marks, and Dogs framework. It is used for strategy, portfolio review, and investment analysis, and this page already shows a real preview of the report content. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
0 marketed products
Alpha Tau Medical Ltd. had 0 marketed cancer products, so no commercial asset could qualify as a true Star. The company stayed tied to clinical development, with no product sales to fund growth; in its latest reported year, revenue was still $0.0 million. That made its BCG profile a pre-commercial pipeline, not a cash-generating market player.
0 revenue-generating franchises
Alpha Tau Medical Ltd. had 0 recurring product revenue in its latest 2025 results, so it did not have a revenue-generating franchise to place in the Stars box. A Star needs high growth and clear market leadership, but Alpha Tau was still in clinical and regulatory build-out, not commercial scale. In 2025, the business was still funding R&D and operating losses rather than harvesting cash from a mature product line.
1 lead platform, Alpha DaRT
Alpha DaRT was Alpha Tau Medical Ltd.'s flagship asset and the closest thing to a Star, but it was still in development and not yet a market leader. The platform was being advanced as a novel radiotherapy for solid tumors, with no commercial sales from the asset in FY2025. That means high upside, but still early-stage execution risk.
Clinical programs in 2 core geographies
Alpha Tau Medical Ltd. kept its clinical work in 2 core geographies, Israel and the United States, which gave it reach but not a commercial moat. In a BCG view, that fits a Star only if trial wins and FDA or other approvals convert the platform into revenue. As of its latest filings, the business still had no durable commercial scale, so clinical breadth alone was not enough.
- 2 core geographies: Israel and US
- Clinical footprint, not moat
- Needs trial wins and approvals
- Commercial scale still not proven
0 proven high-share indications
By end-2025, Alpha Tau Medical had 0 indications with proven dominant share, because none was yet established in routine commercial use. The company was still fighting for clinical validation, not market share, so no product fit the classic Star profile. In BCG terms, this segment stayed at 0 proven high-share indications.
- 0 dominant-share indications
- Validation stage, not commercialization
- No classic Star in 2025
Alpha Tau Medical Had No BCG Star in FY2025
Alpha Tau Medical Ltd. had no commercial Star in FY2025. Alpha DaRT was the closest asset, but it still had 0 product revenue and remained in clinical and regulatory work, not market leadership. With $0.0 million revenue and no dominant-share indication, the BCG Stars box stayed empty.
| Metric | FY2025 |
|---|---|
| Revenue | $0.0m |
| Product sales | 0 |
| Dominant-share indications | 0 |
What is included in the product
Detailed Word Document
Alpha Tau Medical Ltd. BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
One-page Alpha Tau Medical Ltd. BCG Matrix to quickly spot pain points and growth bets for sharper decisions
Reference Sources
Alpha Tau Medical Ltd. Reference Sources provide a credible, traceable basis for key claims, helping decision-makers verify assumptions fast.
Cash Cows
0 approved therapies
Alpha Tau Medical Ltd. had 0 approved therapies, so it had no mature, monetized product to generate steady cash flow. In BCG terms, that means it had no true cash cow to fund R&D, trials, and commercialization. Without an approved therapy, the portfolio had to rely on external capital and burn, not product cash.
0 mature product brands
Alpha Tau Medical Ltd. had 0 mature product brands, so there was no legacy oncology franchise with an entrenched customer base. That meant no low-growth harvest phase; the business was still in build mode in FY2025, focused on R&D, regulation, and first-market adoption. In BCG terms, this leaves no Cash Cow to fund growth, since there was nothing mature enough to generate steady cash.
0 recurring sales streams
Alpha Tau Medical had 0 recurring sales streams, so it could not yet milk a cash cow. In its latest filings, the Company remained pre-revenue or near-zero revenue, so free cash flow still depended on capital raises, not product sales. With no stable franchise in place, cash burn stayed tied to R&D and commercialization spend.
0 high-margin commercial units
Alpha Tau Medical Ltd had 0 high-margin commercial units, so it had no true cash cow in BCG terms. In its latest 2025 reporting, the business was still clinical, with cash mainly tied up in R&D and trial spending rather than repeat sales from approved products.
- No commercial margins yet
- Capital went to clinical trials
- Still in development stage
0 dividend-supporting assets
Alpha Tau Medical Ltd had 0 dividend-supporting assets in FY2025, so no business unit was large enough to fund dividends, debt service, or broad overhead. The portfolio was still pre-commercial and did not generate excess cash, which is why no cash cow was identifiable.
- 0 cash-generating units for dividends
- No excess cash in FY2025
No Cash Cow: Alpha Tau Medical Lacked Approved Therapies in FY2025
Alpha Tau Medical Ltd. had no approved therapies in FY2025, so it had no true Cash Cow. With 0 mature product brands and 0 recurring sales streams, there was no stable cash engine to fund R&D or commercialization.
| Metric | FY2025 |
|---|---|
| Approved therapies | 0 |
| Mature product brands | 0 |
| Recurring sales streams | 0 |
| Cash cow | None |
Get Your Copy
Alpha Tau Medical Ltd. Reference Sources
The Alpha Tau Medical Ltd. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no demo pages or hidden changes—just the full, ready-to-use report. Download it instantly and use it for strategy, analysis, or presentation.
Dogs
0 divestiture-ready brands
Alpha Tau Medical Ltd. disclosed 0 divestiture-ready brands, so there was no obvious Dog to sell or shut down. In FY2025, the portfolio still centered on pipeline creation, not legacy cash drains. That fits a stage where capital is going into clinical build-out, not brand cleanup.
0 low-share legacy products
Alpha Tau Medical Ltd. had 0 low-share legacy products in the Dogs box, because its portfolio was still early-stage, not mature. In FY2025, the Company was still focused on clinical development and had no established legacy franchise to drag on growth. That means the classic Dog profile, low share in a slow market, did not fit Alpha Tau Medical Ltd.
0 break-even business units
Alpha Tau Medical Ltd. disclosed 0 separate business units that merely broke even, so there is no clear Dog on that test. In FY2025, the company was still pre-revenue and its spending was tied to clinical and regulatory work, not product stagnation. That makes a Dog label weak for the current portfolio, because the loss profile looks like clinical burn, not a mature cash drain.
0 obsolete commercial assets
Alpha Tau Medical Ltd. had no obsolete commercial assets to place in the Dogs quadrant. Its core assets were still precommercial and seeking validation, so they had not reached a stage where revenue decline or exit was clear. That means there was no dated product line with a proven shrinking market to wind down.
- Precommercial asset base, not legacy product cash flow
- No dated line with proven decline
- No clear Dog asset to exit
0 trapped cash generators
Alpha Tau Medical’s Dogs were effectively 0 trapped cash generators, so they did not consume capital in a dead commercial asset. The real issue was R&D risk: funding went to pipeline advancement, where value depends on clinical progress, not on a weak existing business line.
- Capital was directed to R&D, not legacy assets.
- Dogs tied up no material strategic value.
- Pipeline risk mattered more than cash drag.
Alpha Tau Medical: No Dogs, Just Precommercial Growth Investment
Alpha Tau Medical Ltd. had 0 Dogs in FY2025: no divestiture-ready brands, no low-share legacy products, and no breakeven cash drains. The portfolio was still precommercial, so losses reflected R&D burn, not a mature declining line. Capital stayed focused on clinical and regulatory build-out.
| Dog test | FY2025 |
|---|---|
| Divestiture-ready brands | 0 |
| Low-share legacy products | 0 |
| Breakeven units | 0 |
Question Marks
Alpha DaRT platform
Alpha DaRT is Alpha Tau Medical Ltd.'s central Question Mark: an investigational solid-tumor platform using diffusing alpha emitters to attack local cancer cells. It has strong upside, but as of 2025 it still needed clear clinical and regulatory proof to scale, with no approved commercial use yet. The platform's value depends on turning early trial signals into approval, reimbursement, and repeatable adoption.
Skin cancer program
Skin cancer was one of Alpha Tau Medical Ltd.'s active clinical focuses, but it was still a Question Mark in the BCG Matrix because the product had not launched commercially. As of 2025, market share was effectively 0% since there were no product sales. The indication is clinically meaningful and could scale fast if trial data stay strong and support approval.
Oral cancer program
Alpha Tau Medical Ltd.'s oral cancer program sat in the clinical pipeline, so it fit BCG Question Mark status: high-growth, but still unproven. Oral cavity cancer remains a major unmet need, with about 377,000 new cases and 177,000 deaths worldwide each year. Alpha Tau still needs stronger efficacy, safety, and physician adoption data before this can move toward Star status.
Pancreatic cancer program
Pancreatic cancer is a high-need tumor, with a 5-year relative survival rate of about 13% in the U.S., so even small clinical gains from Alpha Tau Medical Ltd’s Alpha DaRT could matter a lot. The opportunity is large, but this program still sits in the Question Marks bucket because it has not yet proved clear efficacy or commercial traction.
That makes it a high-upside, high-risk bet: if Alpha DaRT shows meaningful response in a cancer with few good options, value creation could be strong, but failure would leave the program with limited strategic value. In BCG terms, the issue is simple: big market, weak proof.
- High unmet need, low survival
- Large upside if efficacy is shown
- Still unproven, so high risk
Breast cancer program
Alpha Tau Medical Ltd.'s breast cancer program looks like a Question Mark in the BCG matrix: breast cancer is a huge market, with 2.3 million new cases worldwide in 2022 and persistent unmet need in hard-to-treat tumors, but the program was still pre-commercial at end-2025.
So the upside is real if the platform proves clinical benefit, yet the current market share is minimal and execution risk is high.
- Large, growing oncology market
- End-2025: development-stage, not a leader
Alpha Tau’s High-Risk, High-Reward Cancer Bets
Alpha Tau Medical Ltd.’s Question Marks are all Alpha DaRT programs: high-need oncology bets with no 2025 commercial sales yet, so market share stayed near 0% while approval risk remained high. The biggest upside sits in cancers with weak outcomes, like oral, pancreatic, skin, and breast tumors. For example, pancreatic cancer has about a 13% 5-year relative survival rate in the U.S.
| Program | 2025 status | Signal |
|---|---|---|
| Alpha DaRT | Pre-commercial | Core Question Mark |
| Pancreatic | No sales | High need |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.